ACS chemical neuroscience molecule spotlight on Sabril.
Sabril (vigabatrin) oral solution was approved by the FDA on August 21st, 2009 for treatment of infantile spasms in children ages 1 month to 2 years and complex partial seizures in adults (tablets).
Vanderbilt University, Vanderbilt University Medical Center, Department of Pharmacology and Vanderbilt Program in Drug Discovery, Nashville, Tennessee 37232-6600, USA.
Corey R
CR
Hopkins
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors; D000927:Anticonvulsants / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D015394:Molecular Structure; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D016037:Single-Blind Method; D020888:Vigabatrin / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D014786:Vision Disorders / Q000139:chemically induced
D000927:Anticonvulsants; D004791:Enzyme Inhibitors; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin